Lung Cancer

Treatment with gefitinib in the adjuvant setting is associated with enhanced quality of life in patients with early-stage NSCLC and EGFR mutations.

Ensartinib may be a viable treatment option for some forms of secondary ALK alterations.

Similar progression-free survival and 2-year overall survival rates reported for both treatment groups, with more grade ≥3 treatment-related adverse events reported in the afatinib + cetuximab group.

Study evaluated the benefits of afatinib in Asian and non-Asian patients who had not received EGFR-TKI therapy for their EGFR-mutant NSCLC.

Patients with untreated advanced NSCLC with EGFR mutations achieved improved progression-free survival with treatment with gefitinib and carboplatin plus pemetrexed compared with gefitinib alone.

Researchers report higher overall response rate, median duration of response, and median progression-free survival in treatment-naïve patients with a MET exon 14 skipping mutation compared with previously treated patients.

Researchers reported improved overall survival in patients with nonsquamous non–small-cell lung cancer with EGFR mutations.

Tarloxotinib treatment was well tolerated and sizeable percentages of patients in both study cohorts achieved either partial response or stable disease.

Overall response rate, duration of response, and media progression-free survival were highest in the group of treatment-naïve patients with T790M negativity and any MET mutation.

Over the past year, the COVID-19 pandemic has ushered in unprecedented changes in the practice of medicine and dissemination of treatment advances presented in scientific forums.